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Abstract
Gliomas appear to be highly immunosuppressive tumors, with a strong myeloid component. This includes MDSCs, which 
are a heterogeneous, immature myeloid cell population expressing myeloid markers Siglec-3 (CD33) and CD11b and lacking 
markers of mature myeloid cells including MHC II. Siglec-3 is a member of the sialic acid-binding immunoglobulin-like 
lectin (Siglec) family and has been suggested to promote MDSC expansion and suppression. Siglecs form a recently defined 
family of receptors with potential immunoregulatory functions but only limited insight in their expression on immune regula-
tory cell subsets, prompting us to investigate Siglec expression on MDSCs. We determined the expression of different Siglec 
family members on monocytic-MDSCs (M-MDSCs) and polymorphnuclear-MDSCs (PMN-MDSCs) from blood of glioma 
patients and healthy donors, as well as from patient-derived tumor material. Furthermore, we investigated the presence of 
sialic acid ligands for these Siglecs on MDSCs and in the glioma tumor microenvironment. Both MDSC subsets express 
Siglec-3, -5, -7 and -9, with higher levels of Siglec-3, -7 and -9 on M-MDSCs and higher Siglec-5 levels on PMN-MDSCs. 
Similar Siglec expression profiles were found on MDSCs from healthy donors. Furthermore, the presence of Siglec-5 and -9 
was also confirmed on PMN-MDSCs from glioma tissue. Interestingly, freshly isolated glioma cells predominantly expressed 
sialic acid ligands for Siglec-7 and -9, which was confirmed in situ. In conclusion, our data show a distinct Siglec expression 
profile for M- and PMN-MDSCs and propose possible sialic acid–Siglec interactions between glioma cells and MDSCs in 
the tumor microenvironment.
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Introduction
Gliomas are the most common primary brain tumors in 
adults arising from (precursors of) glial cells [2]. Most 
of these tumors show extensive (‘diffuse’) infiltration in 
the brain parenchyma, which precludes complete surgical 
resection. Even after state-of-the-art radio- and chemo-
therapy following surgical resection to the maximum fea-
sible extent, patients with a glioblastoma (i.e., by far the 
most frequent and most malignant form of astrocytoma) 
have a dismal prognosis of only 14–16 months [3, 4].
At the moment, there are no effective FDA-approved 
treatment options available for radio- and chemotherapy-
resistant gliomas. Cancer immunotherapy, where the 
patient’s own immune system is used to eradicate tumor 
cells, may provide a promising approach to specifically 
destroy glioma cells without harming the surrounding 
brain tissue. Numerous immunotherapies are currently 
being investigated in patients with glioma, but so far, the 
induction of tumor cell-specific cytotoxic T cells and sur-
vival benefit are only found in a minority of patients [5–7]. 
Gliomas often show a strong immunosuppressive tumor 
microenvironment with many suppressive immune cells 
including myeloid-derived suppressor cells (MDSCs), 
tumor-associated macrophages and regulatory T cells. This 
hampers immune cell function and limits the efficacy of 
cancer (immuno)therapies [7–10]. Therefore, combination 
therapies are now being actively investigated aiming to 
activate the immune system and to limit the immunosup-
pressive tumor microenvironment, in which myeloid cells 
are thought to play an important role.
We and others have previously reported an increase of 
MDSCs in the blood of glioma patients [11–13]. MDSCs 
express the myeloid lineage markers Siglec-3 (CD33) and 
CD11b but lack markers of mature myeloid cells (MHC II 
molecules HLA-DR,DP,DQ) [14, 15]. There are two main 
MDSC populations, a monocytic (M-) and a polymorpho-
nuclear (PMN-) MDSC population, which are defined by 
the expression of CD14 or CD15, respectively. In addi-
tion, a third subset has been suggested that is lacking the 
myeloid cell lineage markers CD15 and CD14. This is a 
mixed population of early progenitor cells and is, there-
fore, called early-stage MDSCs (e-MDSCs) [14, 16].
Both M-MDSCs and PMN-MDSCs are elevated in the 
blood of glioma patients, with PMN-MDSCs being the 
main MDSC population detected in the tumor tissue [11, 
17]. We have previously shown that PMN-MDSCs from 
glioma patients are potent inhibitors of T-cell function that 
possibly contributes to the immunosuppressive microenvi-
ronment [13]. To interfere with their immunosuppressive 
function, more knowledge about the induction of MDSCs 
and their suppressive phenotype is needed. One of the 
cell surface markers used to identify MDSCs is Siglec-3, 
a member of the sialic acid-binding immunoglobulin-
like lectin (Siglec) family [18]. Interestingly, triggering 
of Siglec-3 in MDSCs has been shown to promote their 
expansion and induce the secretion of immunosuppressive 
cytokines [19].
The human Siglec family consists of 14 members and 
can be divided into two groups: the conserved Siglecs 
and the CD33-related Siglecs. Conserved Siglecs (-1, -2, 
-4, -15) show a high sequence similarity across species, 
whereas CD33-related Siglecs (-3, -5 to -11, -14 and -16) 
display high sequence variability across species [20–22]. 
Siglecs are broadly expressed throughout the immune sys-
tem, but which Siglecs are expressed by MDSCs apart 
from Siglec-3 is largely unknown. Siglecs are type-I trans-
membrane proteins with an extracellular sialic acid-bind-
ing domain and most of them contain a cytoplasmic immu-
noreceptor tyrosine-based inhibitory motif (ITIM). Their 
ligands are sialic acid sugars which are located on glycans 
of membrane glycoproteins and glycolipids of virtually 
all cells in the human body. Sialic acids play an important 
physiological role at the molecular (e.g., regulation of gly-
coprotein stability and function) and cellular level (e.g., 
cell–cell interactions) [23, 24]. Sialic acids can interact 
with Siglecs on the same cell surface in cis or on other 
cells in trans. In general, the interaction between a Siglec 
with its sialic acid ligand initiates an ITIM-mediated sup-
pressive signal [21, 22]. Thereby, Siglecs can dampen 
immune cell activation and possibly contribute to immu-
nological homeostasis [21, 25]. Recent examples demon-
strate the strong immunosuppressive capacity of Siglecs. 
For instance, sialic acid binding to Siglec-2 on B cells 
has been shown to suppress B-cell activation and induces 
tolerance to membrane antigens [26, 27]. Furthermore, we 
have recently shown that monocytic cell activation can be 
dampened via Siglec-3 triggering [28].
A growing body of evidence suggests that tumor cells 
exploit the Siglec family to modulate immune cell func-
tion and to evade detection by the immune system [29–36]. 
Tumor sialic acids have been shown to dampen NK cell-
mediated killing via Siglec-7 and -9 as well as effector T-cell 
function [31, 32, 37]. Furthermore, triggering of Siglec-9 on 
macrophages by tumor-derived sialic acids induced a tumor-
associated macrophage-like phenotype promoting immune 
suppression in the tumor microenvironment [33]. These 
studies suggest that tumor-derived sialic acids modulate the 
function of effector and regulatory immune cell subsets by 
interacting with the Siglec receptor family. To what extent 
sialic acid–Siglec interactions could influence MDSC func-
tion in the tumor microenvironment is largely unknown. 
Therefore, we assessed the expression of Siglec family mem-
bers on MDSCs from glioma patients and healthy donors. In 
addition, the expression of putative cis and trans sialic acid 
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ligands on MDSCs and glioma cells in the tumor microen-
vironment was analyzed.
We found that M- and PMN-MDSCs from blood of gli-
oma patients and healthy donors express multiple Siglecs 
with specific expression profiles, while e-MDSCs show only 
little to no Siglec expression. This could be confirmed on 
glioma-infiltrating PMN-MDSCs. Subsequently, we identi-
fied expression of putative trans Siglec ligands on glioblas-
toma cell lines as well as in patient-derived glioma tissue. 
These data support possible sialic acid–Siglec interactions 
between MDSCs and glioma cells, which could contribute to 
the immunosuppressive role of MDSCs in glioma patients.
Materials and methods
Blood and tumor samples
Peripheral blood samples were collected from 14 healthy 
individuals and from 18 glioma patients undergoing neu-
rosurgical resection or biopsy for intracranial tumors at the 
Radboud University Medical Center (Radboudumc). The 
mean age of the patients was 58 years (range 43–76 years) 
and 56% were males. The healthy donors were anonymous 
and not age and sex matched. All patients had histologi-
cally proven brain tumors diagnosed by neuropathologists 
of the Radboudumc. The tumors were classified according 
to the WHO 2016 Classification of tumors of the Central 
Nervous System [38], and encompassed 1 low-grade diffuse 
astrocytoma, Isocitrate dehydrogenase (IDH)-mutant (WHO 
grade II), 6 oligodendrogliomas, IDH-mutant and 1p/19q-
codeleted (2 WHO grade II, 4 WHO grade III), 2 glioblas-
tomas, IDH-mutant, and 9 glioblastomas, IDH-wildtype. 
Fresh tumor tissue samples were obtained from 6 patients 
by sonic aspiration [3 oligodendrogliomas (2 WHO grade II, 
1 WHO grade III) and 3 glioblastomas (2 IDH-wildtype, 1 
IDH-mutant)]. In addition, histological sections of formalin-
fixed paraffin-embedded glioma tissue were obtained from 4 
patients with glioblastoma (3 IDH-wildtype, 1 IDH-mutant). 
Ten patients had started a 3 × 5 mg dexamethasone regime 
on the day before surgery, while 8 patients received dexa-
methasone at an earlier time point to reduce edema. Imme-
diately after the blood and fresh tumor tissue samples were 
obtained, processing of these samples was started. Flow 
cytometry measurements were performed within 24 h.
Tissue handling
PBMCs were isolated from heparinized venous blood of 
patients and healthy donors using a lymphoprep gradient 
(Lucron Bioproducts, Gennep, the Netherlands). Fresh gli-
oma material was obtained by ultrasonic aspiration or exci-
sion. Ultrasonic aspirates were collected in a sterile suction 
trap and tumor cell suspensions were prepared as described 
previously [11, 39]. Briefly, tumor fragments were washed 
extensively to discard blood and suction fluid. Then, tumor 
fragments were incubated with collagenase type-IA (50 µg/
ml) (Sigma-Aldrich, St Louis, MO), DNAse type-I (10 μg/
ml) (Roche, Mannheim, Germany) and trypsin inhibitor 
(1 μg/ml) (Sigma-Aldrich) in Hank’s Balanced Salt Solu-
tion (HBSS) (Gibco, Invitrogen, Leek, the Netherlands) at 
37 °C followed by mechanical disruption by pipetting. To 
remove granulocytes, including mature neutrophils, tumor 
cell suspensions were placed on a lymphoprep gradient as 
was also used for PBMC isolation.
Flow cytometry and sorting
Using standardized flow cytometry protocols as described 
previously, cells were stained for different membrane mark-
ers using regular antibodies as well as with lectins and 
recombinant Siglec-Fc chimeras to determine their sialic 
acid composition [11, 28]. To exclude dead cells, the cells 
were stained with fixable viability dye eFluor 780 (eBio-
science, Vienna, Austria). Prior to staining, Fc receptors 
were blocked by incubation with 2% human serum. Mem-
brane markers and Siglecs were stained with directly con-
jugated monoclonal antibodies (mAbs) for 20 min on ice. 
Fluorescent mAbs were obtained from BD (San Jose, CA) 
(CD33-APC, HLA-DR,DP,DQ-FITC, CD14-PerCP), Peli-
cluster (Amsterdam, the Netherlands) (CD14-PE), IO-Test 
(CD11b-PE), Biolegend (San Diego, CA) (CD15-PE-Cy7, 
CD45-PerCP, Siglec-5-PE, Siglec-7-PE, Siglec-10-PE), 
Sigma-Aldrich (Siglec-2-PE) and R&D Systems (Siglec-
9-PE). Isotype controls were obtained from BD (IgG1-APC, 
IgG1-PE-Cy7, IgG2a-PE, IgG2a-FITC, and IgG1-PE) and 
Biolegend (IgG2a-PerCP). Cells were washed and resus-
pended in PBS with 1% BSA and 0.02% sodium azide and 
measured on a CyAn (Beckman Coulter, Brea, CA), FAC-
SVerse (BD) or Gallios (Beckman Coulter) flow cytometer. 
For lectin staining, cells were stained with biotinylated lec-
tins Maackia amurensis lectin II (MALII), Sambucus nigra 
agglutinin (SNA-I) and peanut agglutinin (PNA) in carbo-
free blocking solution containing 1 mM  CaCl2+ and 1 mM 
 MgCl2+ (Vector Laboratories, Burlington, NO) for 40 min. 
After washing, the cells were incubated with PE-conjugated 
Streptavidin (BD, Franklin Lakes, NJ). For Siglec ligand 
staining, 0.4 µg/ml recombinant human Siglec-Fc chimera 
(R&D Systems, Minneapolis, MN) was pre-complexed 
with with Alexa Fluor 647-conjugated goat anti-human IgG 
(H + L) antibody (Life Technologies, Burlington, Ontario, 
Canada) in carbo-free blocking solution containing 1 mM 
 CaCl2+ and 1 mM  MgCl2+ and added to the cells for 40 min 
at 4 °C. Cells incubated with Alexa Fluor 647 goat anti-
human IgG antibody only served as control. Data were ana-
lyzed using FlowJo 9.2 (Tree Star Inc, Ashland, OR) and 
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events were gated on single viable cells for further analysis. 
Median fluorescence intensity (MFI) values of Siglec stain-
ings were corrected based on the MFI values of the isotype 
controls to control for flow cytometer type. For sorting of 
MDSC subsets, PBMCs were stained with HLA-DR,DP,DQ-
FITC, CD33-APC, CD14-PE and CD15-PE-Cy7 and sorted 
on a FACS Aria (BD). Data were analyzed using GraphPad 
Prism 5 software.
Quantitative PCR
FACS-sorted cells were resuspended in RNA lysis buffer 
(Zymo Research, Irvine, CA) and stored at − 80 °C until 
RNA isolations were performed using the ZR RNA isola-
tion kit (Zymo Research), according to the manufacturer’s 
instructions. The RNA was treated with DNAase I (ampli-
fication grade; Invitrogen) to remove any genomic DNA 
before being reverse-transcribed into cDNA, as described 
elsewhere [40]. To check for genomic DNA contamina-
tion control samples without reverse transcriptase were 
included. cDNA was stored at − 20 °C until further use. 
Real-time PCR was performed on a CFX96 system (Bio-
Rad, Veenendaal, Netherlands) using SYBR Green reaction 
mix (Sigma-Aldrich) and Siglec expression was calculated 
relative to GAPDH expression. Primer sequences (Sigma-
Aldrich) were derived from the Harvard Primer Bank data-
base (Supplementary Table 1) [41].
Glioma cell culture
Human glioma cell lines U-87 (HTB-14), T98G (CRL-1690) 
and U-251 were grown in Dulbecco’s Modified Eagle’s 
Medium (DMEM) with  GlutaMAX (Gibco) supplemented 
with 10% heat-inactivated FBS (Greiner Bio-one, Fricken-
hausen, Germany), and antibiotic–antimycotic solution (Life 
Technologies) to confluency and passaged using trypsin. The 
cells were used within 3 months after resuscitation and regu-
larly screened for mycoplasma contamination using a detec-
tion kit (Lonza, Walkersville, MD). All cells were incubated 
in a humidified CO2 incubator at 37 °C.
Immunohistochemistry
Siglec ligand expression on paraffin-embedded glioma tis-
sue samples (4 μm) was assessed using human Siglec-Fc 
chimeras. Sections were deparaffinized and rehydrated with 
Xylene, graded ethanol and water. Sections were heated at 
96 °C for 30 min in target retrieval solution, citrate pH 6.0 
(Dako, Agilent Technologies, Santa Clara, CA). After cool-
ing down to room temperature, sections were treated with 
3%  H2O2 in PBS for 15 min, washed with PBS and blocked 
with 20% goat serum. Siglec-7 and -9 ligands were stained 
with 50 nM Siglec-Fc chimeras, pre-complexed with 20 nM 
horseradish peroxidase-conjugated anti-human Fc antibody 
(Thermo Scientific, Waltham, MA) in HBSS at 4 °C. Human 
IgG1 (Sigma-Aldrich) was used as isotype control. Siglec-
Fc binding was detected with a DAB peroxidase substrate 
kit (Vector Laboratories). All tissue sections were counter-
stained with hematoxylin, washed with water, dehydrated 
and mounted with KP-mounting medium (Klinipath, Olen, 
Belgium). Alternatively, sections were treated with 250 mU/
ml Clostridium perfringens sialidase (Sigma-Aldrich) in 
HBSS for 2.5 h at 37 °C and washed with PBS before stain-
ing with Siglec-Fc chimeras. Images were acquired using a 
Leica DM6000 system (Leica, Wetzlar, Germany).
Results
Blood MDSCs express several Siglec family members
Most myeloid cells express several members of the Siglec 
family, but not much is known about Siglec expression 
on MDSCs, except for Siglec-3. Therefore, we assessed 
the expression of the different Siglec family members on 
sorted M-MDSCs  (CD33+ MHC  IIlow/−  CD14+) and PMN-
MDSCs  (CD33+ MHC  IIlow/−  CD15+) from the blood of 
glioma patients (Fig. 1a). In our patient cohort, M-MDSCs 
and PMN-MDSCs represented an average of 5.07% 
(SD = 6.27) and 3.28% (SD = 4.12) of PBMCs, respec-
tively, which is in line with our previously reported data 
[11, 13]. RNA analysis confirmed Siglec-3 expression by 
both MDSC subsets. Additionally, M-MDSCs expressed 
mRNA for Siglec-5, -7, -9, -10, -11, -14, and -16 with 
Siglec-9 showing the highest expression (Fig. 1b). PMN-
MDSCs showed a similar expression profile, but in con-
trast to M-MDSCs, they also expressed Siglec-6, and -8 
at the mRNA level (Fig. 1c). Interestingly, expression of 
Siglec-5 was about 4 times higher in PMN-MDSCs com-
pared to M-MDSCs. Next, we determined Siglec expres-
sion on the cell surface of M- and PMN-MDSCs from 
patients with glioblastomas and lower-grade gliomas 
by flow cytometry using available Siglec antibodies. As 
expected, Siglec-3 (CD33) was detected on the cell sur-
face of both subpopulations, with a higher expression on 
M-MDSCs (Fig. 1a, e–f). Siglec-2, a conserved Siglec 
known to be B-cell specific, was included as a negative 
control and was not found on either M- or PMN-MDSCs 
(Fig. 1d–f) [21]. Siglec-5, -7 and -9 were clearly detected 
on both M- and PMN-MDSCs, with Siglec-5 being the 
most highly expressed on PMN-MDSCs (Fig. 1d–f). In 
contrast to the qPCR data, there was little to no expression 
of Siglec-10 detectable. Additional data have also shown a 
lack of Siglec-6 and -8 expression on both MDSC subsets 
(data not shown). These data confirm that both MDSC 
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Fig. 1  Siglec expression on 
blood MDSCs from glioma 
patients and healthy donors. 
a Gating strategy for MDSCs 
from blood, showing M-, PMN- 
and e-MDSC subsets. b, c 
qPCR analysis of Siglec expres-
sion in M-MDSCs (b) and 
PMN-MDSCs (c) from glioma 
patients. Bar diagrams show 
mean relative Siglec expression 
normalized to GAPDH ± SEM 
(n = 5). d–h Cell surface 
expression of Siglecs on 
MDSC subsets measured by 
flow cytometry. Representative 
histograms show cell surface 
Siglec expression on M-MDSCs 
(left panel) and PMN-MDSCs 
(right panel) (d). The gray 
histograms represent the isotype 
control. Dot plots show median 
fluorescence intensity (MFI) of 
cell surface Siglec expression of 
M-MDSCs and PMN-MDSCs 
derived from blood of glioma 
patients (n = 11–13; 6 lower-
grade gliomas (open circles) 
and 7 glioblastomas (filled 
circles)) (e, f) as well as from 
healthy donors (n = 10–14) (g, 
h). Horizontal lines show the 
mean Siglec expression
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subsets express Siglec-3, -5, -7 and -9, with a generally 
higher Siglec expression on M-MDSCs compared to PMN-
MDSCs, except for Siglec-5 which is highly expressed on 
PMN-MDSCs.
Healthy donors generally have very low amounts of 
MDSCs in their peripheral blood [11, 13, 16]. Neverthe-
less, we also determined Siglec expression on MDSCs pre-
sent in healthy donors. M-MDSCs (0.53% (SD = 0.28) of 
PBMCs) and PMN-MDSCs (2.38% (SD = 2.61) of PBMCs) 
from healthy donors express the same Siglecs as detected on 
MDSC subsets from glioma patients, with similar expres-
sion profiles (Fig. 1g, h). Thus, both M-MDSCs and PMN-
MDSCs express Siglec-3, -5, -7 and -9 in glioma patients 
as well as healthy donors, with a specific expression profile 
dependent on the MDSC subtype.
In addition to these M- and PMN-MDSC populations, 
we also analyzed Siglec expression on the CD15-CD14- 
e-MDSCs (Fig. 1a). In our cohort, the mean percentage of 
this population was 0.73% (SD = 0.50) in glioma patients 
and 2.12% (SD = 2.05) in healthy donors. The expression 
of Siglec-3 on these cells is similar to PMN-MDSCs. Other 
than that, they show little to no Siglec expression (Supple-
mentary Fig. 1). Therefore, we focused on M- and PMN-
MDSCs for further analyses.
Glioma‑infiltrating PMN‑MDSCs express Siglec‑5, ‑7, 
and ‑9
We have previously characterized MDSC infiltration in gli-
oma tissue and found mainly PMN-MDSCs [11, 13]. There-
fore, we additionally analyzed Siglec expression on glioma-
infiltrating PMN-MDSCs. Single cell suspensions derived 
from tumor tissue were stained for PMN-MDSC markers 
and Siglecs. Cells were first gated on single, viable cells and 
CD45 expression (Fig. 2a, left panel). Then, PMN-MDSCs 
were identified as  CD11b+ MHC  IIlow/−  CD15+, because no 
clear Siglec-3 signal above background could be detected 
on these tumor-infiltrating MDSCs, as described previ-
ously [11]. Similar to blood PMN-MDSCs, Siglec-5 and 
-9 could be detected on glioma-infiltrating PMN-MDSCs, 
with the highest expression of Siglec-5 (Fig. 2a, b). Low 
Siglec-7 expression could be detected on glioma-infiltrating 
Fig. 2  Siglec expression on glioma-infiltrating PMN-MDSCs. a–c 
Expression of Siglecs on the surface of PMN-MDSCs and mye-
loid cells in glioma tissue. Gating strategy shows  CD45+ MHC  II+ 
 CD11b+ myeloid cells and  CD45+ MHC  II−  CD11b+  CD15+ PMN-
MDSCs (a, left panels). Representative histograms show Siglec 
expression on myeloid cells (a, upper panel) and PMN-MDSCs (a, 
lower panel). The gray histograms represent the isotype control. 
b, c Bar diagrams show mean Siglec expression ± SEM on glioma-
infiltrating PMN-MDSCs (b) and myeloid cells (c) from three glioma 
patients
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PMN-MDSCs in some patients, while on others it was 
undetectable (Fig. 2a, b). Besides PMN-MDSCs, a group 
of  CD45+  CD11b+ MHC  II+ myeloid cells is present in 
glioma tissue that consists of tumor-infiltrating monocytes, 
tumor-associated macrophages and/or microglia. This group 
expressed Siglec-7 and -9 to a similar extent as  CD33+ MCH 
 II+ cells from blood, but displayed lower levels of Siglec-5 
(Fig. 2a, c, Supplementary Fig. 2). Altogether, these data 
show that glioma-infiltrating PMN-MDSCs consistently 
express Siglec-5 and -9, while other myeloid cells in the 
tumor mainly express Siglec-7 and -9.
MDSCs express cis Siglec ligands
We next investigated the expression of sialic acids on 
MDSCs using the lectins MALII, SNA-I and PNA. These 
Fig. 3  Expression of sialic acids on blood MDSCs from healthy 
donors and glioma patients. a, b Binding of sialic acid-binding lec-
tins MALII (α2,3-linked sialic acid) and SNA-I (α2,6-linked sialic 
acid) and galactose-binding lectin PNA to MDSCs isolated from 
blood of healthy donors. a Representative histograms show lectin 
binding to M-MDSCs (upper panel) and PMN-MDSCs (lower panel) 
as determined by flow cytometry. The gray histograms represent the 
unstained control b) Bar diagram shows MFI ± SEM of lectin binding 
to both MDSC subsets (n = 3). c, d Binding of recombinant Siglec Fc 
chimera to MDSCs from healthy donors (n = 3). Bar diagrams shows 
MFI ± SEM of Siglec Fc binding to M-MDSCs (c) and PMN-MDSCs 
(d). e, f Siglec ligand expression on PMN-MDSCs obtained from the 
blood of glioma patients (n = 5). Bar diagram shows Siglec Fc bind-
ing as MFI ± SEM (e) and histograms show representative Siglec Fc 
binding (f). The gray histograms represent the isotype control
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lectins preferentially recognize α2,3-linked or α2,6-linked 
sialic acids or glycans without sialic acids, respectively. 
M-MDSCs and PMN-MDSCs were gated as shown in 
Fig. 1a and analyzed for lectin binding by flow cytometry. 
Both MDSC subsets expressed α2,3-linked and α2,6-linked 
sialic acids, with the highest levels on M-MDSCs (Fig. 3a, 
b). Interestingly, also PNA binding to M-MDSCs, but not 
to PMN-MDSCs could be observed, indicating the presence 
of uncapped glycans on these cells. Next, we investigated 
which Siglecs could potentially form cis interactions with 
sialic acids present on the MDSCs. PBMCs from healthy 
donors were stained with recombinant human Siglec-Fc 
chimeras together with MDSC markers and analyzed by 
flow cytometry. From all Siglec-Fc chimeras tested, only 
Siglec-7 and Siglec-9 showed binding to both MDCS sub-
sets, with Siglec-9 binding being the highest (Fig. 3c, d). 
In line with the plant-derived lectin stainings, M-MDSCs 
showed generally higher binding of Siglec-7 and -9 chimeras 
compared to PMN-MDSCs. Similar to the healthy donors, 
PMN-MDSCs from blood of glioma patients also expressed 
ligands for Siglec-7 and Siglec-9 (Fig. 3e, f). Here, the 
higher expression of Siglec-9 ligands compared to Siglec-7 
ligands was not detected. Siglec-5 ligands were detected on 
PMN-MDSCs in 3 out of 5 glioma patients. No signal for 
Siglec-2, -3 or -10 binding was found. Altogether, our data 
show that both MDSC subsets express ligands for Siglec-7 
and Siglec-9 that may form cis interactions with the corre-
sponding Siglec receptors present on these cells.
Glioblastoma cell lines and patient‑derived glioma 
cells express trans Siglec ligands
Many tumors show aberrantly high expression of sialic 
acid-carrying glycans that possibly interact with Siglecs 
expressed on MDSCs and other infiltrating immune cells. 
To investigate whether glioma cells express sialic acids that 
can serve as ligands for Siglecs, three different human glio-
blastoma cell lines (U-87, T98G and U251) were probed 
with recombinant human Siglec-Fc chimeras and analyzed 
by flow cytometry. While no staining of ligands for Siglec-2, 
-3, -5 and -10 was observed, ligands for Siglec-7 and -9 
were detected on all three cell lines (Fig. 4a). Expression 
of Siglecs themselves on the cell surface of the glioma cell 
lines was not detected (data not shown).
Next, we investigated whether the results from glioblas-
toma cell lines resemble the Siglec ligand expression as it 
occurs on glioma cells in situ. Therefore, single cell sus-
pensions were prepared from freshly isolated glioma tissue 
(from glioblastoma n = 1 and oligodendrogliomas n = 3) and 
stained with anti-CD45 antibody and recombinant human 
Siglec-Fc chimeras. Glioma cells were gated as single, via-
ble cells lacking CD45 expression, the marker for infiltrating 
immune cells. On primary glioma cells, we mainly detected 
ligands for Siglec-7 and -9, while some patients also showed 
low levels of Siglec-3 and -5 ligand staining (Fig. 4b, c). The 
presence of the two most dominant ligands, for Siglec-7 and 
-9, in glioma tissue was confirmed by immunohistochem-
istry (Fig. 4d). Specificity of Siglec-7 and -9 Fc chimera 
binding was confirmed by the loss of signal after hydroly-
sis of sialic acids by sialidase. Staining did not completely 
disappear, probably due to aspecific staining caused by the 
sialidase [42].
These data show that mainly sialic acid ligands for 
Siglec-7 and -9 are expressed by glioblastoma cell lines and 
on patient-derived glioma tissue. Interestingly, Siglec-7 and 
-9 were present on both MDSC subsets found in the blood 
and expression of Siglec-9 was also confirmed on PMN-
MDSCs from glioma tissue, suggesting possible trans 
interactions between glioma cells and MDSCs. In addition 
to MDSCs, other myeloid (regulatory) cells present in the 
tumor could interact with glioma cells via Siglec-7 and -9.
Discussion
The presence of MDSCs is increased in the blood of patients 
with glioma in a grade-dependent manner and they infil-
trate the glioma tissue [11, 13]. Siglec-3 is a widely used 
surface marker for MDSCs and has been suggested to pro-
mote MDSC expansion as well as their suppressive pheno-
type [18, 19, 21]. Expression of Siglec-3 on MDSCs was 
already well established, but expression of other Siglec fam-
ily members on MDSCs has not been investigated so far. 
Here, we show that M-MDSCs and PMN-MDSCs isolated 
from the blood of glioma patients and healthy donors also 
express Siglec-5, -7 and -9 on their cell surface. M-MDSCs 
expressed higher Siglec-3, -7 and -9 levels compared to 
PMN-MDSCs, whereas Siglec-5 was highest on PMN-
MDSCs. Expression of Siglec-5 and -9 was also confirmed 
on PMN-MDSCs derived from glioma tissue. E-MDSCs 
have only low Siglec expression. Additionally, we showed 
that glioma cells mainly express ligands for Siglec-7 and -9. 
These data imply that sialic acid–Siglec interactions between 
Fig. 4  Glioma cell lines and freshly resected glioma cells express 
trans ligands for Siglecs. a Three glioblastoma cell lines were stained 
with recombinant Siglec Fc chimera and analyzed by flow cytometry. 
Bar diagrams show mean MFI ± SEM of Siglec Fc chimera binding 
to U-87, T98G and U251 cells of three independent experiments. b, 
c Expression of Siglec ligands on glioma cells obtained from freshly 
resected tumor tissue (glioblastoma n = 1, oligodendroglioma n = 3). 
Representative histograms show binding of Siglec Fc chimera to 
 CD45− cells isolated from glioma tissue (b). Bar graphs show mean 
fluorescent intensity ± SEM of Siglec Fc binding (c). d Immunohis-
tochemistry for Siglec-7 and Siglec-9 ligand expression in paraffin-
embedded glioma tissue untreated (upper row) or treated with siali-
dase (lower row). Data are representative of 4 glioblastoma patients
◂
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glioma cells and PMN-MDSCs in the tumor microenviron-
ment can occur that could influence MDSC function.
For Siglec-3, -5, -7 and -9, we found mRNA transcripts 
as well as cell surface protein expression on both MDSC 
subsets. In addition, expression of Siglec-11, -14 and -16 
was found on the mRNA level, but their expression on 
the cell surface is not yet confirmed. Siglec-10 expres-
sion was detected by qPCR in both M-MDSC and PMN-
MDSCs, but protein expression could not be confirmed 
with the existing monoclonal antibodies. Also Siglec-6 and 
-8 membrane expression could not be detected. In general, 
M-MDSCs expressed higher levels of Siglecs compared 
to PMN-MDSCs, except for higher levels of Siglec-5 on 
PMN-MDSCs. Noteworthy, the antibody against Siglec-5 
is cross-reactive to Siglec-14, but the higher expression of 
Siglec-5 in PMN-MDSCs was also found on mRNA level. 
The biological relevance of the different expression pat-
terns of Siglec-3, -5, -7 and -9 between both MDSC sub-
sets remains to be determined. In addition to the M- and 
PMN-MDSCs, we have also determined Siglec expression 
on the CD15-CD14- e-MDSCs. This population, however, 
is more prone to contamination by other cells, and there-
fore inclusion of the lineage markers CD3, CD19 and CD56 
is important to characterize them as true lineage-negative 
MDSCs [14]. These lineage markers were not present in our 
MDSC panel and therefore, the levels of e-MDSCs found in 
our patients and controls might be an overestimation. We 
were able to include these lineage markers in four of our 
patients and could confirm low Siglec-3, -5 and -7 expres-
sions on pure lineage-negative e-MDSCs. The limited num-
bers of patients and healthy donors included in this study 
preclude meaningful statements about possible differences 
between Siglec expression on MDSCs from patient(group)
s or healthy donors.
In addition to expressing Siglec receptors, both MDSC 
subsets also expressed α2,3-linked and α2,6-linked sialic 
acids. M-MDSC showed overall higher expression levels of 
sialic acids compared with PMN-MDSCs. So far, the role 
of sialic acids in MDSC biology is largely unknown. Our 
findings suggest that these sialic acids could serve as cis or 
trans ligands for Siglec-5, -7 and -9 receptors on the sur-
face of MDCS or other immune cell subsets interacting with 
MDSCs. Staining of MDSCs with recombinant Siglec-2, -3 
and -10 Fc chimeras was negative, yet putative sialic acid 
ligands for these Siglecs could be masked [43]. Future stud-
ies should investigate the role of cis (MDSCs) and trans 
(tumor) sialic acid–Siglec interactions in MDSC biology and 
their relevance for cancer immunotherapy.
Most Siglecs have one or more ITIM motifs allowing 
them to modulate immune cell activation and function. 
In MDSCs, Siglec-3 signaling has been shown to induce 
secretion of suppressive cytokines after forming a func-
tional ligand–receptor pair, for example, with S100A9 
[19]. Whether this interaction is sialic acid dependent has 
not been investigated [19]. We have previously shown that 
serum from glioma patients contains increased levels of 
S100A8/9 compared to healthy individuals, suggesting 
that MDSCs in glioma patients could gain a more suppres-
sive phenotype due to enhanced Siglec-3–S100A9 interac-
tions [13]. On patient-derived glioma cells, we could only 
detect very low levels of ligands for Siglec-3; so, this is not 
very likely to affect MDSC function. In addition, we can-
not detect Siglec-3 on intra-tumoral PMN-MDSCs, which 
could be caused by Siglec-3 downregulation or be a conse-
quence of the isolation process. However, we did observe a 
clear expression of Siglec-7 and -9 ligands on glioma cells 
ex vivo as well as in situ and the corresponding Siglecs are 
present on both blood MDSCs and (at least Siglec-9) on 
tumor-infiltrated PMN-MDSCs. These findings indicate that 
glioma cells could, thus, interact with MDSCs via the sialic 
acid–Siglec-9 axis. It has been shown for other immune cell 
types that sialic acid–Siglec-7/-9 interactions can dampen 
immune cell activation or effector function thereby shap-
ing the immunosuppressive tumor microenvironment [25, 
29, 31–33, 35, 37, 44]. Further research needs to determine 
whether glioma sialic acids can indeed interact with Siglec-7 
and -9 on MSDCs and/or other myeloid cells in the tumor 
microenvironment and what the functional consequences 
are.
In conclusion, our data show that MDSCs from glioma 
patients and healthy donors express Siglec-3, -5, -7 and 
-9. On patient-derived glioma cells, ligands are found for 
Siglec-7 and -9, supporting possible sialic acid-dependent 
interactions between glioma cells and MDSCs in the tumor 
microenvironment. It may be highly rewarding to further 
elucidate whether this interaction occurs in the tumor micro-
environment and whether sialic acid–Siglec interactions 
influence the suppressive function of MDSCs. Such stud-
ies may provide new opportunities to interfere with MDSC 
function and may potentiate anti-glioma immunotherapy.
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